FGFR inhibitors pemigatinib and infigratinib, are both effective in patients with FGFR2 fusions with pemigatinib recently approved in the second-line setting for patients with iCCA [31, 32]. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.